摘要
目的统计分析北京地区近6年来膦甲酸钠的不良反应报告,为膦甲酸钠的安全合理应用提供依据。方法收集2008年3月-2014年12月北京市药品不良反应监测中心数据库中膦甲酸钠不良反应报告,并对152例不良反应统计分析ADR报告类型、ADR发生时间、患者年龄、性别和民族分布、严重不良反应、过敏史、给药途径、剂型、用量、用药原因、患者既往ADR史、ADR累及器官/系统及表现、ADR关联性评价结果、ADR处理及预后。结果膦甲酸钠致ADR在31-60岁发生率较高,55.3%的ADR发生于用药后24 h内,临床表现复杂多样,涉及机体多个器官或系统,主要和严重的不良反应为肾损害及癫痫发作。结论膦甲酸钠的安全性是临床应关注的问题,应在合理使用的基础上,监测并及时处理其不良反应。
OBJECTIVE To analyze the reports of foscarnet-induced adverse drug reaction （ADR） in Beijing area in the recent 6 years, and to provide reference for rational use of foscarnet. METHODS One hundred and fifty-two reports of ADR from March 2008 to December 2014 induced by foscarnet received by Beijing drug adverse reaction monitoring center were collected. The type and time of ADR,the age of patient, the gender and nation of patient, serious adverse reactions, allergy history, administration, dosage, preparation, the indication,ADR history,ADR involved organ and system , the causal relationship, treatments and prognosis were retrospectively analyzed. RESULTS The ADR induced by foscarnet were more often occurred in patients aged from 31 to 60, with 55.3% appearing within 24 h after drug use. The clinical presentation was complex and diverse, which involved different systems and organs, predominantly the lesion of renal function and epilepticseizures. CONCLUSION Safe to use with foscarnet is worth paying attention by clinicans, who should detect and deal with ADR of foscarnet in time on basis of rational use.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2015年第18期1634-1638,共5页
Chinese Pharmaceutical Journal
基金
国家临床重点专科建设项目
